| Year |
Citation |
Score |
| 2015 |
Mitra S, Vierra M, Levitan B, Jokadze G, Farmer A. Abstract B129: Novel miniprep system for rapid purification of recombinant proteins and antibodies on high capacity membranes Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B129 |
0.328 |
|
| 2013 |
Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB, Huang Z. Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. Acs Medicinal Chemistry Letters. 4. PMID 24167659 DOI: 10.1021/Ml3004523 |
0.517 |
|
| 2013 |
Huan X, Shi J, Lim L, Mitra S, Zhu W, Qin H, Pasquale EB, Song J. Unique structure and dynamics of the EphA5 ligand binding domain mediate its binding specificity as revealed by X-ray crystallography, NMR and MD simulations. Plos One. 8: e74040. PMID 24086308 DOI: 10.1371/Journal.Pone.0074040 |
0.301 |
|
| 2013 |
Duggineni S, Mitra S, Noberini R, Han X, Lin N, Xu Y, Tian W, An J, Pasquale EB, Huang Z. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochemical Pharmacology. 85: 507-13. PMID 23253822 DOI: 10.1016/J.Bcp.2012.12.005 |
0.482 |
|
| 2013 |
Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, Kitada S, Pasquale EB, Fisher PB, Pellecchia M. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 128-37. PMID 23155185 DOI: 10.1158/1078-0432.Ccr-12-2654 |
0.399 |
|
| 2012 |
Stanford SM, Panchal RG, Walker LM, Wu DJ, Falk MD, Mitra S, Damle SS, Ruble D, Kaltcheva T, Zhang S, Zhang ZY, Bavari S, Barrios AM, Bottini N. High-throughput screen using a single-cell tyrosine phosphatase assay reveals biologically active inhibitors of tyrosine phosphatase CD45. Proceedings of the National Academy of Sciences of the United States of America. 109: 13972-7. PMID 22891353 DOI: 10.1073/Pnas.1205028109 |
0.62 |
|
| 2012 |
Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, Koolpe M, Zhang Z, Dahl R, Pasquale EB, Pellecchia M. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. Journal of Medicinal Chemistry. 55: 2427-36. PMID 22329578 DOI: 10.1021/Jm201743S |
0.34 |
|
| 2011 |
Noberini R, Mitra S, Salvucci O, Valencia F, Duggineni S, Prigozhina N, Wei K, Tosato G, Huang Z, Pasquale EB. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity. Plos One. 6: e28611. PMID 22194865 DOI: 10.1371/Journal.Pone.0028611 |
0.471 |
|
| 2010 |
Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry. 49: 6687-95. PMID 20677833 DOI: 10.1021/Bi1006223 |
0.499 |
|
| 2009 |
Mitra S, Duggineni S, Koolpe M, Dail M, Zhu X, Huang Z, Pasquale EB. Abstract B201: Selective peptides for targeting EphA2 in cancer cells Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B201 |
0.553 |
|
| 2008 |
Mitra S, Barrios AM. Identifying selective protein tyrosine phosphatase substrates and inhibitors from a fluorogenic, combinatorial peptide library. Chembiochem : a European Journal of Chemical Biology. 9: 1216-9. PMID 18412190 DOI: 10.1002/Cbic.200800046 |
0.654 |
|
| 2007 |
Mitra S, Barrios AM. A series of peptide-based, fluorogenic probes for protein tyrosine phosphatase activity. Analytical Biochemistry. 370: 249-51. PMID 17662953 DOI: 10.1016/J.Ab.2007.06.012 |
0.661 |
|
| 2005 |
Mitra S, Barrios AM. Highly sensitive peptide-based probes for protein tyrosine phosphatase activity utilizing a fluorogenic mimic of phosphotyrosine. Bioorganic & Medicinal Chemistry Letters. 15: 5142-5. PMID 16203147 DOI: 10.1016/J.Bmcl.2005.08.054 |
0.659 |
|
| Show low-probability matches. |